Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Hyun Jung Jin 2 Articles
Biological treatments for severe asthma
Hyun Jung Jin
Yeungnam Univ J Med. 2020;37(4):262-268.   Published online September 11, 2020
DOI: https://doi.org/10.12701/yujm.2020.00647
  • 6,777 View
  • 179 Download
  • 9 Crossref
AbstractAbstract PDF
Severe asthma patients comprise about 3% to 13% of all asthma patients, but they have higher hospital utilization rates and higher medical costs than those of nonsevere asthma patients. Treatment methods for severe asthma patients are still lacking; however, the recent development of biologics is expected to have a positive effect. The biological therapies developed so far are mainly aimed at treating asthma patients with type 2 inflammation. These biologics have been found to reduce symptoms of asthma, improve lung function, reduce the use of oral corticosteroids, and improve quality of life of patients. This article reviews the mechanism of action and indications for approved biologics and discusses what should be considered when choosing biologics.

Citations

Citations to this article as recorded by  
  • Current and Novel Biologic Therapies for Patients with Asthma and Nasal Polyps
    Hanna K. Mandl, Jessa E. Miller, Daniel M. Beswick
    Otolaryngologic Clinics of North America.2024; 57(2): 225.     CrossRef
  • Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities
    Sara Naharro-González, Clara Lorente-Sorolla, José Manuel Rodrigo-Muñoz, Marcela Valverde-Monge, Erwin Javier Pinillos-Robles, Diana Betancor, Mar Fernández-Nieto, Diana Sánchez-Mellado, Marta Gil-Martínez, Jessica Mireya Santillán-Coello, José Miguel Vil
    Biomolecules.2024; 14(1): 126.     CrossRef
  • Biologic Therapies across Nasal Polyp Subtypes
    Kody G. Bolk, Sarah K. Wise
    Journal of Personalized Medicine.2024; 14(4): 432.     CrossRef
  • Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies
    Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young, Nathorn Chaiyakunapruk
    Journal of Asthma.2023; 60(9): 1702.     CrossRef
  • Tackling the cytokine storm using advanced drug delivery in allergic airway disease
    Vyoma K. Patel, Sukriti Vishwas, Rajan Kumar, Gabriele De Rubis, Shakti D. Shukla, Keshav Raj Paudel, Bikash Manandhar, Thakur Gurjeet Singh, Dinesh Kumar Chellappan, Monica Gulati, Indu Pal Kaur, Venkata Sita Rama Raju Allam, Philip M. Hansbro, Brian G.
    Journal of Drug Delivery Science and Technology.2023; 82: 104366.     CrossRef
  • The evolving landscape of immunotherapy for the treatment of allergic conditions
    Aarti Pandya, Esosa Adah, Bridgette Jones, Rachel Chevalier
    Clinical and Translational Science.2023; 16(8): 1294.     CrossRef
  • Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis
    Chin Kook Rhee, Jung-Won Park, Heung-Woo Park, You Sook Cho
    Allergy, Asthma & Immunology Research.2022; 14(2): 182.     CrossRef
  • The role of peripheral eosinophilia in diagnosing lung disorders: experience from a single pneumonological center
    Justyna Fijołek, Elzbieta Wiatr, Dorota Piotrowska-Kownacka, Kazimierz Roszkowski-Sliz
    Multidisciplinary Respiratory Medicine.2021;[Epub]     CrossRef
  • Advances in the science and treatment of respiratory diseases
    Jin Hong Chung
    Yeungnam University Journal of Medicine.2020; 37(4): 251.     CrossRef
Microbiologic distribution and clinical features of nontuberculous mycobacteria in the tertiary hospital in Daegu.
Kyung Soo Hong, June Hong Ahn, Eun Young Choi, Hyun Jung Jin, Kyeong Cheol Shin, Jin Hong Chung, Kwan Ho Lee
Yeungnam Univ J Med. 2015;32(2):71-79.   Published online December 31, 2015
DOI: https://doi.org/10.12701/yujm.2015.32.2.71
  • 2,145 View
  • 24 Download
  • 3 Crossref
AbstractAbstract PDF
BACKGROUND
Recent studies have shown that the nontuberculosis mycobacterium (NTM) recovery rate in clinical cultures has increased within Korea. However, another study conducted by a secondary hospital within Daegu reported different results. Therefore, the purpose of this study is to understand and evaluate the microbiological distribution and clinical features of NTM in Daegu. METHODS: A retrospective study was conducted on 11,672 respiratory specimens undergoing acid fast bacilli (AFB) culture from 6,685 subjects who visited Yeungnam University Respiratory Center from January 2012 to December 2013. RESULTS: Of the 11,672 specimens undergoing AFB culture, 1,310 specimens (11.2%) showed positive results. Of these specimens, NTM was recovered from 587 specimens, showing a recovery rate of 44.8%. Identification test for NTM was performed on 191 subjects; the results were as follows: M. avium-intracellulare complex (MAC) 123 (64.4%), M. abscessus 20 (10.5%), M. kansasii 12 (6.3%), and 33 other NTM germ strains. Of the 382 subjects with NTM, 167 were diagnosed with pulmonary NTM disease (43.7%), however virulence differed depending on NTM strain. Multivariate analysis showed that nodular bronchiectasis, the nodules, and finding consistent with cavity under imaging study were statistically significant for triggering pulmonary NTM disease. AFB culture showing MAC and M. abscessus was statistically significant as well. Positive predictive value for NTM polymerase chain reaction (NTM-PCR) was 88.6%. CONCLUSION: Results for NTM recovery rate within the Daegu area were similar to those for the Seoul metropolitan area. We can assume that NTM infection is increasing in our community, therefore AFB-positive subjects (1) should undergo NTM-PCR, (2) should have their culture results checked for differentiation of mycobacterium tuberculosis complex (MTB) from NTM, and (3) undergo NTM identification test to confirm its type. Administration of treatment with the above results should be helpful in improving the patients' prognosis.

Citations

Citations to this article as recorded by  
  • Distribution and Antimicrobial Resistance of Non-Tuberculous Mycobacteria during 2015∼2020: A Single-Center Study in Incheon, South Korea
    Jiwoo Kim, Hyo-Jin Ju, Jehyun Koo, Hyeyoung Lee, Hyeonhwan Park, Kyungcheol Song, Jayoung Kim
    The Korean Journal of Clinical Laboratory Science.2021; 53(3): 225.     CrossRef
  • Study on the Prevalence of Lung Disease of Non-Tuberculosis Mycobacterium Isolated from Respiratory Specimens in Gwangju Second Hospital over the Last 10 Years
    Hae-Gyeong Baek
    The Korean Journal of Clinical Laboratory Science.2020; 52(4): 349.     CrossRef
  • Recovery Rates of Non-Tuberculous Mycobacteria from Clinical Specimens Are Increasing in Korean Tertiary-Care Hospitals
    Namhee Kim, Jongyoun Yi, Chulhun L. Chang
    Journal of Korean Medical Science.2017; 32(8): 1263.     CrossRef

JYMS : Journal of Yeungnam Medical Science